Heterogeneous HIV-1 Reactivation Patterns of Disulfiram and Combined Disulfiram+Romidepsin Treatments.
Fiche publication
Date publication
avril 2019
Journal
Journal of acquired immune deficiency syndromes (1999)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROHR Olivier
Tous les auteurs :
Kula A, Delacourt N, Bouchat S, Darcis G, Avettand-Fenoel V, Verdikt R, Corazza F, Necsoi C, Vanhulle C, Bendoumou M, Burny A, De Wit S, Rouzioux C, Rohr O, Van Lint C
Lien Pubmed
Résumé
Few single latency-reversing agents (LRAs) have been tested in vivo, and only some of them have demonstrated an effect, albeit weak, on the decrease of latent reservoir. Therefore, other LRAs and combinations of LRAs need to be assessed. Here, we evaluated the potential of combined treatments of therapeutically promising LRAs, disulfiram and romidepsin.
Mots clés
Anti-HIV Agents, administration & dosage, Cell Line, Depsipeptides, administration & dosage, Disulfiram, administration & dosage, Drug Therapy, Combination, HIV Infections, drug therapy, HIV-1, drug effects, Humans, Virus Activation, drug effects, Virus Latency, drug effects
Référence
J. Acquir. Immune Defic. Syndr.. 2019 04 15;80(5):605-613